SCHEMBL30862744

SCHEMBL30862744

Cc1cc(C(F)(F)F)ccc1NC(=O)[C@H]1CCc2c(N3CCN(C(=O)OC(C)(C)C)CC3)c(=O)n3nc(C4=CCOCC4)nc3n21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.48
▸ RAF1 P04049 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ MAPT P10636 2/20 0.32
▸ TP53 P04637 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ ALK Q9UM73 3/20 0.32
▸ SYK P43405 1/20 0.32
▸ ENPP2 Q13822 1/20 0.32
▸ MCL1 Q07820 1/20 0.31
▸ BTK Q06187 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TBK1 Q9UHD2 1/20 0.31
▸ HDAC4 P56524 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862712 1.00 WRN (0.48) WRNRAF1BRAFMAPTTP53
SCHEMBL30862758 0.91 WRN (0.44) WRNMAPTLMNANPC1RAB9A
SCHEMBL30862692 0.91 WRN (0.44) WRNMAPTLMNANPC1RAB9A
SCHEMBL30862767 0.90 WRN (0.47) WRNRAF1BRAFMAPTTP53
SCHEMBL30862757 0.90 WRN (0.47) WRNRAF1BRAFMAPTTP53
SCHEMBL30862711 0.90 WRN (0.47) WRNRAF1BRAFMAPTTP53
SCHEMBL30862748 0.90 WRN (0.47) WRNRAF1BRAFMAPTTP53
SCHEMBL30862709 0.90 WRN (0.47) WRNRAF1BRAFMAPTTP53
SCHEMBL30862843 0.89 WRN (0.47) WRNRAF1BRAFBTK
SCHEMBL30862695 0.89 WRN (0.47) WRNRAF1BRAFBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 — — EP disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R WRN 2992/4885RAF1 960/4885BRAF 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback